The comparison of efficacy of primary transdiagnostic protocol based on repetitive negative thinking with Barlow transdiagnostic protocol in symptoms reduction of people with co-occurrence anxiety and depression disorders.

The comparison of efficacy of primary transdiagnostic protocol based on repetitive negative thinking with Barlow transdiagnostic protocol (2011) in symptoms reduction of people with co-occurrence anxiety and depression disorders.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013090414564N1

Enrollment

Registered

2013-12-29

Start date

2013-11-11

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Generalized anxiety disorder. Condition 2: Obsessive-compulsive disorder. Condition 3: Post-traumatic stress disorder. Condition 4: Social phobia disorder. Condition 5: Panic disorder. Condition 6: Major depressive disorder. Generalized anxiety disorder Obsessive-compulsive disorder Post-traumatic stress disorder Social phobia disorder Panic disorder Recurrent depressive disorder

Interventions

Intervention 1: The first intervention is consisted of 12 sessions (each session is 45 minutes in a week) of transdiagnostic therapy based on repetitive negative thinking for experimental group 1. Int

Behavior

The first intervention is consisted of 12 sessions (each session is 45 minutes in a week) of transdiagnostic therapy based on repetitive negative thinking for experimental group 1.

The second intervention is consisted of 12 sessions (each session is 45 minutes in a week) of Barlow transdiagnostic therapy (2011) for experimental group 2.

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criterion: Having diagnostic criteria more than one co-occurrence anxiety and depression disorders based on structural clinical interview for axis I; Undergraduate student; Patient consent for participate in research; The availability of the patient during treatment and follow-up period; Stable on the same dose if use psychotropic medications. Exclusion criteria: Having any kind of psychosis disorder; Having bipolar mood disorder (type I or II); Having any kind of severe personality disorder; The history of drug abuse; giving another psychological treatment, such as cognitive behavior therapy, behavior therapy, cognitive therapy or group therapy simultaneous with treatment or in past; Having serious problem in during the study such as suicidal thoughts or change in rates of psychotropic medications dose.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Repetitive negative thinking. Timepoint: Before treatment, at the end of treatment, and after a 2-month follow-up. Method of measurement: Repetitive Negative Thinking Questionnaire.;Anxiety. Timepoint: Before treatment, at the end of treatment, and after a 2-month follow-up. Method of measurement: Depression Anxiety Stress Scale-21.;Depression. Timepoint: Before treatment, at the end of treatment, and after a 2-month follow-up. Method of measurement: Depression Anxiety Stress Scale-21.;Emotional dysregulation. Timepoint: Before treatment, at the end of treatment, and after a 2-month follow-up. Method of measurement: Difficulties in Emotion Regulation Scale.;Metacognition beliefs. Timepoint: Before treatment, at the end of treatment, and after a 2-month follow-up. Method of measurement: Metacognition Beliefs Questionnaire.;Experiential avoidance. Timepoint: Before treatment, at the end of treatment, and after a 2-month follow-up. Method of measurement: The Multidimensional Experiential Avoidance Questionnaire.	—

Measure

Time frame

Repetitive negative thinking. Timepoint: Before treatment, at the end of treatment, and after a 2-month follow-up. Method of measurement: Repetitive Negative Thinking Questionnaire.;Anxiety. Timepoint: Before treatment, at the end of treatment, and after a 2-month follow-up. Method of measurement: Depression Anxiety Stress Scale-21.;Depression. Timepoint: Before treatment, at the end of treatment, and after a 2-month follow-up. Method of measurement: Depression Anxiety Stress Scale-21.;Emotional dysregulation. Timepoint: Before treatment, at the end of treatment, and after a 2-month follow-up. Method of measurement: Difficulties in Emotion Regulation Scale.;Metacognition beliefs. Timepoint: Before treatment, at the end of treatment, and after a 2-month follow-up. Method of measurement: Metacognition Beliefs Questionnaire.;Experiential avoidance. Timepoint: Before treatment, at the end of treatment, and after a 2-month follow-up. Method of measurement: The Multidimensional Experiential Avoidance Questionnaire.

—

Secondary

Measure	Time frame
General function. Timepoint: Before treatment, at the end of treatment, and after a 2-month follow-up. Method of measurement: Work and Social Adjustment Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Akbari

Shahed University

Akbari.psy@gmail.com+98 21 6602 1735

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026